About Insilicos
Insilicos was a Healthcare company based in Seattle (United States) founded in 2003 by Erik Nilsson, Brian Pratt, and Bryan Prazen. It delivers software solutions for proteomic analysis. It operates on a B2B model. The company is recorded as dissolved. Its focus areas include Biotechnology, Life Sciences, Analysis Software and Proteomic Tools. Its competitors include Cyrus Biotechnology, Vividion Therapeutics and Seer; 3 of its 3 listed competitors have raised funding.
Company details
Insilicos, established in 2003, excels in advancing biotech innovations, life sciences, analysis software, and proteomic tools. Delivers software solutions for proteomic analysis. Committed to advancing standards, it focuses on innovation, efficiency, and delivering value to clients worldwide. It continues to evolve, meeting industry challenges with strategic approaches.
- Headquarters Seattle, United States
- Founders Erik Nilsson, Brian Pratt, Bryan Prazen
- SectorsHealthcare
- Website insilicos.com
- Social Facebook
- Latest Funding Round$203.6K (USD), Grant
Aug 2011
- Investors
Funding Insights of Insilicos
- Total Rounds 8
- Last Round Grant — $203,600
- First Round $673,624
(Aug 2007)
- Investors Count 1
All 8 funding rounds of Insilicos with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
1 investors in total: 1 institutional.
Investors in Insilicos
Insilicos has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Insilicos
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Insilicos
3 people are tracked at Insilicos (3 in leadership).
| Name | Role | Group |
|---|---|---|
Erik Nilsson | Founder, President | Leadership |
Brian Pratt | Co-Founder | Leadership |
Bryan Prazen | Co-Founder | Leadership |
Complete people profiles for Insilicos
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Insilicos
3 dated milestones of Insilicos across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Insilicos is founded.
- Funding First funding round of $674K.
- Funding Latest funding round, Grant, of $204K.
Competitors of Insilicos
Insilicos has 3 listed competitors in our database, 3 of them funded. They include Cyrus Biotechnology, Vividion Therapeutics and Seer.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| cyrusbio.com | 2014 | Seattle, United States | $31.99M | 23 | Cloud-based protein-modeling software is developed for drug discovery. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| seer.bio | 2017 | San Francisco, United States | $127.5M | 89 | Proteomics platform developed for early cancer and neurological disease detection. |
Detailed competitors of Insilicos
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Insilicos
Websites that share an audience with Insilicos (insilicos.com).
Websites whose visitors overlap most with Insilicos. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| allozyne.com | 100% | View details | |||
| paraytec.com | 98% | View details | |||
| labvantage.com | 89% | 36K | #874,578 | View details |
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Insilicos (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Insilicos
Insilicos was founded in 2003 and raised its 1st funding round 4 years after it was founded.
Insilicos is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Insilicos, established in 2003, excels in advancing biotech innovations, life sciences, analysis software, and proteomic tools. Delivers software solutions for proteomic analysis. Committed to advancing standards, it focuses on innovation, efficiency, and delivering value to clients worldwide. It continues to evolve, meeting industry challenges with strategic approaches.
Insilicos's top competitors include Vividion Therapeutics, Cyrus Biotechnology and Seer.
Insilicos has 1 investor. Key investors include HHS.